Abstract
Background Left ventricular hypertrophy (LVH) is characterized by increased left ventricular myocardial mass (LVM) and is associated with adverse cardiovascular outcomes. Traditional LVH diagnosis based on rule-based criteria using limited electrocardiogram (ECG) features lacks sensitivity. Accurate LVM evaluation requires imaging techniques such as magnetic resonance imaging or computed tomography (CT) and provides prognostic information beyond LVH. This study proposed a novel deep learning-based method, the eLVMass-Net, together with sex-specific and various processing procedures of 12-lead ECG, to estimate CT-derived LVM.
Methods 1,459 ECG-LVM paired data were used in this research to develop a deep-learning model for LVM estimation, which adopted ECG signals, demographic information, QRS interval duration and absolute axis values as the input data. ECG signals were encoded by a temporal convolutional network (TCN) encoder, a deep neural network ideal for processing sequential data. The encoded ECG features were concatenated with non-waveform features for LVM prediction. To evaluate the performance of the predicting model, we utilized a 5-fold cross-validation approach with the evaluation metrics, mean absolute error (MAE) and mean absolute percentage error (MAPE).
Results The eLVMass-Net has achieved an MAE of 14.33±0.71 and an MAPE of 12.90%±1.12%, with input of single heartbeat ECG waveform and lead-grouping. The above results surpassed the performance of best state-of-the-art method (MAE 19.51±0.82, P = 0.04; MAPE 17.62%±0.78%; P = 0.07) in 292(±1) test data under 5-fold cross-validation. Adding the information of QRS axis and duration did not significantly improve the model performance (MAE 14.33±0.71, P = 0.82; MAPE 12.90%±1.12%; P = 0.85). Sex-specific models achieved numerically lower MAPE for both males (−2.71%, P=0.48) and females (−2.95%, P=0.71), respectively. The saliency map showed that T wave in precordial leads and QRS complex in limb leads are important features with increasing LVM, with variations between sexes.
Conclusions This study proposed a novel LVM estimation method, outperforming previous methods by emphasizing relevant heartbeat waveforms, inter-lead information, and non-ECG demographic features. Furthermore, the sex-specific model is a rational approach given the distinct habitus and features in saliency map between sexes.
What is new?
The eLVMass-Net used ECG encoders with lead grouping, a unique feature that more properly reflects the electrical orientation of left ventricle.
The sex-specific deep learning model is able to discriminate inter-gender differences of ECG features as shown by saliency maps.
What are the clinical implications?
The eLVMass-Net outperforms current state-of-the-art deep learning models for estimating left ventricular mass.
A more accurate estimation of left ventricular mass could improve quality of care for comorbidities such as hypertension from easily accessible ECG.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is not a clinical trial or a prospective interventional study.
Funding Statement
Supported by a research grant from National Science and Technology Council, Taiwan (R.O.C.) (MOST 111-2314-B-002-275).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was further approved by the Institutional Review Board of National Taiwan University Hospital(NTUH-REC No. 202012128RINA).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
National Taiwan University Hospital has the proprietary right to all patient data involved in the study, which was derived from the Taiwan CVAI dataset.
